8 known cases. View patent page →
Hatch-Waxman ANDA litigation. Consent judgment entered June 15, 2022 (Judge Esther Salas): permanent injunction; all claims/counterclaims dismissed with prejudice. Patents-in-suit expressly included 8,828,427 plus '262, '939, '428, '467, '5939.
Hatch-Waxman ANDA litigation filed after Dr. Reddy's ANDA (Mar. 29, 2019) and Paragraph IV notice (May 31, 2019); asserted '262, '3939, '428, '427, and '467. Outcome not confirmed in the sources reviewed.
Celgene filed a § 271 patent infringement action against Synthon in M.D.N.C. asserting US 8,198,262, 8,673,939, 8,735,428, and 8,828,427. The case was terminated July 25, 2018 by a stipulation of dismissal, described as a parallel/companion filing to the New Jersey action.
Hatch-Waxman ANDA patent-infringement suit involving pomalidomide (ANDA No. 213234). Patents asserted included U.S. 8,198,262, 8,673,939, 8,735,428, 8,828,427, and U.S. 9,993,467. A consent judgment enjoined Dr. Reddy's from infringing the patents-in-suit until expiration and dismissed all claims, counterclaims, and defenses with prejudice.
Ancillary third-party subpoena-enforcement matter docketed against the '3939 patent's litigation entry and ancillary to the pomalidomide patent litigation. No patent infringement claims were asserted.
Antitrust/purchaser-overcharge action alleging monopolization of pomalidomide. The '3939 patent is cited in the complaint as part of the alleged scheme to delay generic entry. Motion to dismiss denied in part; proceeding.
Antitrust/purchaser-overcharge action against Celgene. The '3939 patent is expressly identified in the complaint as part of the alleged monopolization scheme concerning pomalidomide. Case is pending.
Antitrust/purchaser-overcharge action against Celgene and Bristol Myers Squibb. The complaint references the '3939 patent and the method-of-treatment patent tree as part of the alleged monopolization scheme. Case is pending.